$146.73 Million in Sales Expected for Amarin Co. plc (NASDAQ:AMRN) This Quarter

Analysts expect Amarin Co. plc (NASDAQ:AMRN) to post sales of $146.73 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Amarin’s earnings, with the lowest sales estimate coming in at $125.25 million and the highest estimate coming in at $156.00 million. Amarin reported sales of $100.79 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 45.6%. The business is scheduled to announce its next earnings report on Wednesday, July 29th.

On average, analysts expect that Amarin will report full-year sales of $664.29 million for the current financial year, with estimates ranging from $605.74 million to $700.30 million. For the next fiscal year, analysts expect that the business will report sales of $824.21 million, with estimates ranging from $270.80 million to $1.10 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Amarin.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The firm had revenue of $155.00 million for the quarter, compared to analysts’ expectations of $150.06 million. Amarin had a negative net margin of 3.67% and a negative return on equity of 4.05%. The firm’s quarterly revenue was up 111.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.05) earnings per share.

AMRN has been the topic of several recent analyst reports. BidaskClub cut shares of Amarin from a “sell” rating to a “strong sell” rating in a report on Saturday, May 30th. Cantor Fitzgerald reissued a “buy” rating and set a $35.00 target price on shares of Amarin in a report on Monday, June 15th. ValuEngine raised shares of Amarin from a “hold” rating to a “buy” rating in a report on Friday, May 1st. HC Wainwright reissued a “buy” rating on shares of Amarin in a report on Friday, May 1st. Finally, Aegis increased their target price on shares of Amarin from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, May 4th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $17.21.

AMRN traded down $0.22 during trading on Friday, hitting $6.70. The company had a trading volume of 5,024,867 shares, compared to its average volume of 6,895,756. The company has a market cap of $2.58 billion, a PE ratio of -111.67 and a beta of 2.71. The business has a 50-day moving average of $7.12 and a 200-day moving average of $13.23. Amarin has a 1-year low of $3.95 and a 1-year high of $26.12.

Hedge funds have recently added to or reduced their stakes in the stock. NWK Group Inc. acquired a new stake in shares of Amarin in the 4th quarter worth about $47,000. Partner Investment Management L.P. bought a new position in Amarin in the 4th quarter valued at about $81,000. Sunbelt Securities Inc. bought a new position in Amarin in the 4th quarter valued at about $24,924,000. Exane Derivatives bought a new position in Amarin in the 1st quarter valued at about $29,000. Finally, Amundi Pioneer Asset Management Inc. grew its position in Amarin by 13.7% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 7,394 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 893 shares in the last quarter. 44.36% of the stock is currently owned by institutional investors and hedge funds.

Amarin Company Profile

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

Read More: Most Active Stocks

Get a free copy of the Zacks research report on Amarin (AMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.